Kognezil

Donepezil hydrochloride, the active ingredient in Kognezil, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of cognitive symptoms associated with Alzheimer’s disease in adults.

GNH USA supplies Kognezil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Donepezil acts on the cholinergic pathway to improve cognition in Alzheimer’s disease.

Alzheimer's disease (mild): Improves memory and daily functioning in early‑stage patients. Alzheimer's disease (moderate): Helps maintain cognitive abilities and slows functional decline. Alzheimer's disease (overall): Reduces severity of cognitive symptoms and supports daily activities.

Donepezil may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea - Diarrhea - Insomnia - Muscle cramps - Fatigue - Loss of appetite

Serious or Rare Side Effects: - Bradycardia or other cardiac conduction abnormalities - Severe vomiting or dehydration - Seizures - Hepatotoxicity - Allergic reactions such as rash or angioedema

When prescribing Donepezil, clinicians should consider several safety measures.

Assess cardiac function: Obtain baseline ECG in patients with known heart disease. Monitor for gastrointestinal bleeding: Use caution with concurrent NSAIDs or anticoagulants. Use caution in asthma or COPD: May exacerbate bronchospasm. Avoid in patients with known hypersensitivity to donepezil or other acetylcholinesterase inhibitors. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Donepezil can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent use with strong anticholinergics: antagonizes therapeutic effect. - Combination with other acetylcholinesterase inhibitors: risk of cholinergic overload. - Use with drugs that prolong QT interval: heightened arrhythmia risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of gastrointestinal bleeding. - Beta‑blockers: potential additive bradycardia. - CYP2D6 inhibitors (e.g., fluoxetine): can raise donepezil plasma levels.